Clinical Trials Directory

Trials / Completed

CompletedNCT01352689

CKD-828(80/2.5mg) Pharmacokinetic Study_2nd

Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics of Telmisatan 80mg and S-Amlodipine 2.5mg as a Fixed Dose Combination Tablet Compared With Combination Therapy in Healthy Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
67 (actual)
Sponsor
Chong Kun Dang Pharmaceutical · Industry
Sex
Male
Age
20 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the pharmacokinetic characteristics of CKD-828(Fixed Dose Combination Tablet; Telmisartan and S-Amlodipine) in healthy volunteer.

Conditions

Interventions

TypeNameDescription
DRUGCKD-828(FDC)Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
DRUGCombination TherapyDrug: Telmisatan 80mg Tablet, Oral, Once Daily Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily

Timeline

Start date
2011-04-01
Primary completion
2011-05-01
Completion
2011-05-01
First posted
2011-05-12
Last updated
2011-06-08

Source: ClinicalTrials.gov record NCT01352689. Inclusion in this directory is not an endorsement.

CKD-828(80/2.5mg) Pharmacokinetic Study_2nd (NCT01352689) · Clinical Trials Directory